[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)

Summary

This was a Phase II, multi-center, open label, single dose study in patients with tumor types known to overexpress Gastrin-Releasing Peptide Receptor (GRPR), including breast, prostate, colorectal, Non-Small Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC).

Timeline

Start

2018-07-03

Primary completion

2019-06-20

Completion

2019-07-05

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment was stopped before the target sample size was achieved.”

Drugs

Indications